02.09.26 -- The Quiet Case For Trusting CDMO Pricing

Join our panel for a fireside chat about the formulation and delivery of spray-dried biologics across oral solids, nasal, pulmonary and injectable (high concentration and encapsulated biologics) dosage forms. Expert discussion around the benefits and applications of spray drying in the development and manufacture of biologics alongside excipient selection, development timelines, testing methods and GMP manufacture. Register Now.

Sterile injectable manufacturing demands built‑in contamination control, monitoring, skilled personnel, and robust quality systems, far beyond sterility testing, to ensure reliable CDMO performance.

Comprehensive sterile injectable fill/finish capabilities can help accelerate development timelines and reduce overall costs. See flexible operational options and available capacity.

Explore the changing landscape of parenteral delivery, considering the pros and cons of intravenous, subcutaneous, and intramuscular formulations, and how new technologies are reshaping drug delivery.

Antibody-drug conjugate manufacturing requires, among other things, unidirectional flow and air locks for people and materials. Facilities often lack these attributes.

All future submissions are expected to align with FDA's draft guidance that clarifies the agency's expectations for evaluating and controlling Essential Drug Delivery Output (EDDO) requirements.

Integrating advanced digitalization solutions and prioritizing data security can accelerate drug development while reducing costs and ensuring consistency across a global network.

When choosing between protein expression formats such as transient versus stable pools, considerations include speed, cost, titre, and product quality.

The heterogeneity of a biologic product has implications for the final therapy's safety and efficacy. Evaluate challenges associated with charged variants, including mAbs and fusion proteins.

Antibody-drug conjugates' manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill & finish.

Outlined are the inherent benefits of PFS and how they relate to the delivery of drugs, how SARS-CoV-2 could be fueling an explosive increase in PFS demand, and how a partnership with a CDMO is key.

Standardized, continuously optimized facility design enables efficient and reliable biomanufacturing that improves quality, accelerates timelines, and ensures consistent performance across sites.

Learn how to implement PAT effectively with a roadmap that covers techniques, validation, data integrity, and lifecycle strategies to help teams improve quality, control, and productivity.

AI is shifting from experimentation to execution in drug development. This OPCU special edition explores where AI delivers value today—across discovery, CMC, and quality—and how CDMOs and sponsors can collaborate to reduce risk, improve quality, and accelerate timelines, with practical guidance on readiness, regulatory considerations, and sponsor expectations.

Partner with a premier global CDMO to move from discovery to commercialization faster, powered by dual-site manufacturing, 20+ years of expertise, and advanced ADC conjugation.

Integrated device assembly, labeling, and packaging solutions streamline pharma delivery, ensuring compliance, scalability, and patient-centric design from clinical trials to commercial production.

With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.

Gain insight into a CDMO with global, end-to-end mammalian manufacturing solutions, proven expertise, flexible capacity, and a strong track record in regulatory compliance that can support your company.

Designed as a dedicated, short-range logistics service for the life sciences, this solution reinforces chain of custody, ensures near real-time visibility, and preserves product integrity from start to finish.

Leverage development strategies and enable an optimized process for mAb development and manufacturing, efficiency, and speed with quality, and high titers with lower-cost workflows.